OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Nov 12, 2020 • 14min
Ifosfamide
Our Landmarks of OncoPharm series returns with Ifosfamide
Nov 5, 2020 • 15min
BELLINI
The BELLINI trial of venetoxlax in multiple myeloma was put on hold last year due to increased mortality. It's now published (https://doi.org/10.1016/S1470-2045(20)30525-8), so we take a look at the data and the myriad of supportive care concerns.
Oct 29, 2020 • 17min
Updates On Keynote-426, Ph+ ALL, & Post - AlloHSCT Maintenance
Discussing three recent publications:
1. Updated results of Keynote-426 (https://doi.org/10.1016/S1470-2045(20)30436-8)
2. Ph+ ALL tx with dasatinib/prednisone --> blinatumomab (https://www.nejm.org/doi/full/10.1056/NEJMoa2016272)
3. Decitabine + G-CSF to prevent AML relapse following alloHSCT (https://ascopubs.org/doi/pdf/10.1200/JCO.19.03277)
Oct 21, 2020 • 15min
Monthly Immunotherapy Expanded Approvals Update
Another month, another 2 expanded FDA-approvals: nivolumab/ipilimumab for malignant pleural mesothelioma and pembrolizumab for relapsed/refractory classical Hodgkin's lymphoma.
Oct 15, 2020 • 14min
Fulvestrant's Fumbled Dosing
Fulvestrant's standard dosing is now 500 mg IM on Days 1, 14, 29 & then monthly thereafter. Its initial FDA-approved doing was half that with no loading dose, 250 mg IM monthly.
So, how did we come to underdose an antineoplastic for almost a decade?
Oct 8, 2020 • 19min
Dexamethasone
Foundations in #OncoPharm returns to discuss everyone's favorite antineoplastic, dexamethasone, which is also an anti-emetic, and an oncology pre-med among other things.
Oct 1, 2020 • 16min
IMpower 110 & Checkmate 153
Another week, another 2 studies of checkpoint inhibitors in NSCLC to talk about.
IMpower 110: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346
Checkmate-153: https://ascopubs.org/doi/full/10.1200/JCO.20.00131
Sep 24, 2020 • 24min
ESMO 2020 & Beyond
Updates from ESMO 2020 & more on:
Bladder Cancer (JAVELIN Bladder 100 & DANUBE)
Lung Cancer (ADAURA & CROWN)
Breast Cancer (ASCENT, IMPASSION 130/131, monarchE)
And the first major publication of drugging the "undrugable" KRAS
Sep 17, 2020 • 14min
TAX 327
The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory.
TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720
Sep 11, 2020 • 12min
Pralsetinib
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
